4 results match your criteria: "Inserm U941-Paris 7 Diderot University[Affiliation]"
Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
Intervirology
September 2012
Virology Department, INSERM U941-Paris 7 Diderot University, Saint-Louis Hospital-APHP, Paris, France.
Objective: The genetic barrier for the evolution of integrase inhibitors (INIs) including raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG) resistance was compared between HIV-1 subtypes CRF01_AE and B.
Methods: Analysis of 66 substitutions associated with INI resistance at 41 amino acid positions in 144 nucleotide sequences (109 HIV-1 subtype CRF01_AE and 35 HIV-1 subtype B) of integrase-coding region of polymerase gene derived from INI-naive patients.
Results: 28/41 studied amino acid positions were conserved, leading to a similar genetic barrier between the two subtypes.
Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication.
HIV Med
October 2012
Virology Department, Saint-Louis Hospital-APHP, Inserm U941-Paris 7 Diderot University, Paris, France.
Objectives: Heavily treatment-experienced patients with good virological control could be at risk of virological failure on switching to a new regimen if pre-existing drug resistance is not taken into account. We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens.
Patients And Methods: All 169 patients enrolled in the Agence Nationale de Recherche sur le SIDA (ANRS) 138-intEgrase inhibitor MK_0518 to Avoid Subcutaneous Injections of EnfuviRtide (EASIER) trial had already received three antiretroviral drug classes [nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)] and had plasma HIV-1 RNA<400 copies/ml at baseline.
Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised.
J Clin Virol
April 2012
Virology Dpt, Inserm U941-Paris 7 Diderot University, Saint-Louis Hospital-APHP, Paris, France.
Background: Recently, cases of chronic hepatitis E have been identified in immunocompromised patients.
Objectives: To evaluate the prevalence of anti-HEV IgG antibodies and the persistence of HEV-RNA in sera of immunocompromised patients with regular follow-up at Saint-Louis Hospital in Paris, France.
Study Design: 307 samples collected from 261 HIV-infected patients and 46 kidney transplant (KT)-patients were retrospectively tested for the presence of the following hepatitis E virus (HEV) infection markers: anti-HEV IgM antibodies, anti-HEV IgG antibodies, anti-HEV IgG avidity index, and HEV-RNA.
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
AIDS
September 2010
Virology Department, INSERM U941-Paris 7 Diderot University, Saint-Louis Hospital-APHP, Paris, France.
Article Synopsis
- - Early integration of HIV proviral DNA into the genome makes it difficult to eradicate the virus even when using effective HAART; integrase inhibitors like raltegravir show potential in reducing proviral DNA levels.
- - The EASIER-ANRS 138 trial found that switching treatment from enfuvirtide to raltegravir maintained viral suppression in patients with a viral load below 400 copies/ml and showed stable total HIV-1 DNA levels over 48 weeks.
- - The study indicated that there were no significant changes in total HIV DNA levels or 2-LTR circle detection over the 48-week follow-up, suggesting that the viral reservoir remains stable in patients on effective HAART.